Immune Response Completed Phase 1 Trials for Nelfinavir (DB00220)

IndicationStatusPhase
DBCOND0034832 (Immune Response)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00346619Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in AdultsTreatment